Feedback
Settings

Settings

Goto Application

294,945 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 29,495
1.3168422CELL-BASED ASSAYS AND KITS FOR ASSESSING SERUM CHOLINERGIC RECEPTOR ACTIVITY
CA - 06.02.2023
Int.Class G01N 33/567
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
 Appl.No 3168422 Applicant CENTRE FOR ADDICTION AND MENTAL HEALTH Inventor NOBREGA, JOSE
Provided herein are methods for determining the level of muscarinic acetylcholine receptor subtype-1 (M1 receptor) anticholinergic activity in a blood serum sample. The methods include radioactive methods and non-radioactive methods. The method comprises the steps of removing protein from the blood serum sample by treatment with perchloric acid (PCA) to produce a PCA-treated serum sample, incubating the PCA-treated serum sample with a membrane preparation from cultured cells expressing the M1 receptor and an M1 receptor ligand; detecting an amount of binding of the M1 receptor ligand to the M1 receptor and comparing the amount of binding to a standard to determine the level of M1 receptor anticholinergic activity in the blood serum sample. Alternatively, the method may comprise loading calcium sensitive dye into the cells and testing serum from a subject in a fluorescence assay to determine the anticholinergic activity relative to a sample known to contain little to no anticholinergic activity. Also provided are kits for performing the method.
2.WO/2023/004624MYELOMA BIOMARKER LGALS3BP AND USE THEREOF
WO - 02.02.2023
Int.Class C12Q 1/6876
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
 Appl.No PCT/CN2021/108914 Applicant BEIJING SUNBIO BIOTECH CO., LTD. Inventor YU, Xiaobo
Provided are a product for detecting an LGALS3BP gene or an LGALS3BP protein and the use thereof in the preparation of a tool for the diagnosis and/or prognosis of myeloma. Further provided are an inhibitor of the LGALS3BP gene or the LGALS3BP protein and the use thereof in the preparation of a drug for the treatment of myeloma.
3.WO/2023/005959COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
WO - 02.02.2023
Int.Class A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
 Appl.No PCT/CN2022/108136 Applicant THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor IP, Nancy Yuk Yu
Provided are new compositions and methods useful for the treatment, prevention, and potential cure of Alzheimer's Disease by disrupting the genomic locus of IL1LR1 gene including rs1921622 and/or other 574 sST2-associated genomic sites and/or 3' -UTR of sST2 gene/transcript.
4.20230034185DISEASE RESISTANCE LOCI IN ONION
US - 02.02.2023
Int.Class A01H 1/04
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
HNEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
1Processes for modifying genotypes
04Processes of selection
 Appl.No 17855475 Applicant Seminis Vegetable Seeds, Inc. Inventor Lowell Black

The present disclosure provides for unique onion plants with disease resistance and desirable bulb color and their progeny. Such plants may comprise an introgressed QTL associated with multiple disease resistance coupled with a desirable bulb color. In certain aspects, compositions, including distinct polymorphic molecular markers, and methods for producing, breeding, identifying, selecting, and the like of plants or germplasm with disease resistance and/or desirable bulb color are provided.

5.20230034216MULTIPLEXED SPATIAL CAPTURE OF ANALYTES
US - 02.02.2023
Int.Class C12Q 1/6874
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
6874involving nucleic acid arrays, e.g. sequencing by hybridisation
 Appl.No 17873788 Applicant 10x Genomics, Inc. Inventor Felice Alessio Bava

Provided herein are methods, compositions, and kits for multiplex spatial detection of analytes in a biological sample.

6.20230037138PARAXANTHINE-BASED CAFFEINE SUBSTITUTE COMPOSITIONS AND METHOD OF USE THEREOF IN SLOW CAFFEINE METABOLIZERS
US - 02.02.2023
Int.Class A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
 Appl.No 17875368 Applicant Ingenious Ingredients, LP Inventor Ralf Jäger

The disclosed compositions methods relate to a dietary supplement for subjects with slow caffeine metabolism and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite in a slow caffeine metabolizer subject.

7.20230030983FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US - 02.02.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No 17655519 Applicant ASTEX THERAPEUTICS LTD Inventor Jayaprakash KARKERA

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

8.WO/2023/008329BIOMARKER FOR DETECTING HEPATOCYTES WITH BILE DUCTULAR PROLIFERATION
WO - 02.02.2023
Int.Class C12Q 1/6813
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
 Appl.No PCT/JP2022/028466 Applicant THE UNIVERSITY OF TOKYO Inventor SEIKI, Motoharu
The present invention provides a method for detecting a biomarker for detecting hepatocytes with bile ductular proliferation, said method comprising a step for detecting laminin γ2 single chain or a nucleic acid encoding the same as the biomarker in a specimen.
9.WO/2023/007805TEST METHOD AND TEST SYSTEM
WO - 02.02.2023
Int.Class C12M 1/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
 Appl.No PCT/JP2022/009372 Applicant SHIMADZU CORPORATION Inventor HARADA, Tomoyuki
One embodiment of a test method according to the present invention is carried out through specimen pooling using a test system equipped with a pre-treatment device for mixing a plurality of individual specimens to prepare a pooled specimen, a test device for analyzing the pooled specimen or an individual specimen, a management terminal capable of communicating with each of the pre-treatment device and the test device, a database that can be accessed from the management terminal, and a display unit, wherein: before preparation of the pooled specimen, software for pre-treatment device management that is installed in the management terminal has a step for receiving input of specimen information relating to the individual specimens and the pooled specimen through a user operation, a step for saving the received specimen information in the database, and a step for displaying the results of analysis of one or a plurality of pooled specimens on the display unit (S16); and when at least one pooled specimen is positive, the software for test device management that is installed in the management terminal has a specimen designation step (S18) for receiving designation or selection of a specific pooled specimen, and a specimen information input step (S19) for acquiring specimen information about the plurality of individual specimens associated with the designated or selected pooled specimen from the database, inserting the acquired specimen information at a prescribed position in a specimen information input screen image for setting the specimen information on a specimen to be tested, and displaying the specimen information on the display unit.
10.WO/2023/004460METHODS OF DETECTING AND/OR DIAGNOSING PANCREATIC CANCER
WO - 02.02.2023
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
 Appl.No PCT/AU2022/050794 Applicant HUDSON INSTITUTE OF MEDICAL RESEARCH Inventor LUNDY, Joanne Margaret
The present invention relates to methods of detecting and/or diagnosing pancreatic cancer in a subject. The present invention also relates to methods of resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a subject.
# -